At a glance
ClinicalIndex Comparison RecordPhase 1Active· 22 enrolled
Drug / intervention
Sapanisertib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Advanced NSCLC Patients
In Brief
A Phase 1 clinical trial evaluating Sapanisertib and Telaglenastat Hydrochloride for Leptomeningeal Neoplasm and 6 related conditions. Active but no longer recruiting, targeting 22 participants across 7 sites.
Detailed Summary
This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
CountriesUnited States
Collaborators--
Timeline
Phase 1Active
20202021202220232024202520262027
First PostedJan 2020
Enrollment StartOct 2020
Primary CompletionNov 2025
TodayJul 2026
Study CompletionNov 2026
First PostedJan 31, 2020
Enrollment StartOct 26, 2020
Primary CompletionNov 21, 2025
Study CompletionNov 21, 2026
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 6.4 years ago
Interventions
Sapanisertibdrug
Given PO
Telaglenastat Hydrochloridedrug
Given PO